A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects

GSK3389404 is a liver‐targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins. This first‐in‐human, randomized, double‐blind, phase 1 study assessed the safety and pharmacokinetics of GSK3389404 administered subcutaneously (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kelong, Cremer, Jennifer, Elston, Robert, Oliver, Stuart, Baptiste‐Brown, Sharon, Chen, Shuguang, Gardiner, David, Davies, Matt, Saunders, Joanne, Hamatake, Robert, Losos, Jan, Leivers, Martin, Hood, Steve, van der Berg, Frans, Paff, Melanie, Ritter, James M., Theodore, Dickens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767536/
https://www.ncbi.nlm.nih.gov/pubmed/30861337
http://dx.doi.org/10.1002/cpdd.670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767536/
https://www.ncbi.nlm.nih.gov/pubmed/30861337
http://dx.doi.org/10.1002/cpdd.670

Ejemplares similares